Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma

Shweta Gera, Mark Ettel, Gabriel Acosta-Gonzalez, Ruliang Xu

Research output: Contribution to journalShort survey

12 Citations (Scopus)

Abstract

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)300-309
Number of pages10
JournalWorld Journal of Hepatology
Volume9
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Cholangiocarcinoma
Histology
Neoplasms
Hepatocellular Carcinoma
Stem Cells
Liver
alpha-Fetoproteins
Tumor Biomarkers
Hepatitis
Hepatocytes
Fibrosis
Ethanol
Therapeutics
Biomarkers
Transplants
Biopsy
Injections
Incidence

Keywords

  • Cholangiocellular carcinoma
  • Classification
  • Combined hepatocellular-cholangiocellular carcinoma
  • Hepatic progenitor cell(s)
  • Hepatocellular carcinoma
  • Histogenesis

ASJC Scopus subject areas

  • Hepatology

Cite this

Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. / Gera, Shweta; Ettel, Mark; Acosta-Gonzalez, Gabriel; Xu, Ruliang.

In: World Journal of Hepatology, Vol. 9, No. 6, 01.01.2017, p. 300-309.

Research output: Contribution to journalShort survey

Gera, Shweta ; Ettel, Mark ; Acosta-Gonzalez, Gabriel ; Xu, Ruliang. / Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. In: World Journal of Hepatology. 2017 ; Vol. 9, No. 6. pp. 300-309.
@article{03fc67f041e24ff58be6adacd5067e1b,
title = "Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma",
abstract = "Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0{\%}-4.7{\%} of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.",
keywords = "Cholangiocellular carcinoma, Classification, Combined hepatocellular-cholangiocellular carcinoma, Hepatic progenitor cell(s), Hepatocellular carcinoma, Histogenesis",
author = "Shweta Gera and Mark Ettel and Gabriel Acosta-Gonzalez and Ruliang Xu",
year = "2017",
month = "1",
day = "1",
doi = "10.4254/wjh.v9.i6.300",
language = "English (US)",
volume = "9",
pages = "300--309",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "6",

}

TY - JOUR

T1 - Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma

AU - Gera, Shweta

AU - Ettel, Mark

AU - Acosta-Gonzalez, Gabriel

AU - Xu, Ruliang

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.

AB - Combined hepatocellular-cholangiocarcinoma (CHC) is a rare tumor with poor prognosis, with incidence ranging from 1.0%-4.7% of all primary hepatic tumors. This entity will be soon renamed as hepato-cholangiocarcinoma. The known risk factors for hepatocellular carcinoma (HCC) have been implicated for CHC including viral hepatitis and cirrhosis. It is difficult to diagnose this tumor pre-operatively. The predominant histologic component within the tumor largely determines the predominant radiographic features making it a difficult distinction. Heterogeneous and overlapping imaging features of HCC and cholangiocarcinoma should raise the suspicion for CHC and multiple core biopsies (from different areas of tumor) are recommended before administering treatment. Serum tumor markers CA19-9 and alpha-fetoprotein can aid in the diagnosis, but it remains a challenging diagnosis prior to resection. There is sufficient data to support bipotent hepatic progenitor cells as the cell of origin for CHC. The current World Health Organization classification categorizes two main types of CHC based on histo-morphological features: Classical type and CHC with stem cell features. Liver transplant is one of the available treatment modalities with other management options including transarterial chemoembolization, radiofrequency ablation, and percutaneous ethanol injection. We present a review paper on CHC highlighting the risk factors, origin, histological classification and therapeutic modalities.

KW - Cholangiocellular carcinoma

KW - Classification

KW - Combined hepatocellular-cholangiocellular carcinoma

KW - Hepatic progenitor cell(s)

KW - Hepatocellular carcinoma

KW - Histogenesis

UR - http://www.scopus.com/inward/record.url?scp=85014052638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014052638&partnerID=8YFLogxK

U2 - 10.4254/wjh.v9.i6.300

DO - 10.4254/wjh.v9.i6.300

M3 - Short survey

AN - SCOPUS:85014052638

VL - 9

SP - 300

EP - 309

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 6

ER -